Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 9/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isobutane SCHEMBL29141206 | 0.88 | CTSK (0.56) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL14923444 | 0.87 | CTSK (0.62) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL28366233 | 0.87 | CTRB1 (0.58) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL5724608 | 0.87 | CTSK (0.62) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL2723504 | 0.87 | CTSK (0.62) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL15271597 | 0.87 | CTRB1 (0.58) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL21906489 | 0.87 | CTRB1 (0.58) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL1570467 | 0.87 | CTRB1 (0.61) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL15664942 | 0.87 | CTRB1 (0.61) | CTRB1CTSKATMCTSSCTSL | |
| SCHEMBL1570465 | 0.87 | CTRB1 (0.61) | CTRB1CTSKATMCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | CTRB1 1532/4885CTSK 731/4885ATM 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.